Aug 05, 2022 09:36 AM (GMT+8) · EqualOcean
Fineimmu recently closed its pre-Series A financing round worth nearly CNY 100 million. The round was led by Huafang Capital. Revo venture capital and Yabao pharmaceutical also participated in this deal. Junyi capital acted as the exclusive financial advisor. The financing funds will be used mainly for accelerating its IND filing and phase I clinical trials of multiple cell therapy products. It is Fineimmu's first time to disclose its financing information and research and development progress since its establishment in 2017.